Abstract
Non alcoholic fatty liver disease (NAFLD) is defined as fat accumulation exceeding 5% to 10% by the weight of the liver, in the absence of other causes of steatosis. NAFLD is strongly associated with metabolic diseases, such as metabolic syndrome. At present, insulin resistance, elevated concentrations of free fatty acids and oxidants, and an imbalance between different cytokines have been identified as the common pathophysiological elements underlying both NAFLD and metabolic syndrome. Emerging evidence also considers NAFLD as the hepatic manifestation of metabolic syndrome and supports a possible direct role of fat liver in cardiovascular risk assessment. Further investigations are needed to better understand the role of NAFLD, as an independent active factor in metabolic syndrome and associated cardiovascular disease.
Keywords: Atherosclerosis, metabolic syndrome, non-alcoholic fatty liver disease, cardiovascular risk
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Does Non-Alcoholic Fatty Liver Disease (NAFLD) Increase Cardiovascular Risk?
Volume: 8 Issue: 4
Author(s): Fabrizio Montecucco and Francois Mach
Affiliation:
Keywords: Atherosclerosis, metabolic syndrome, non-alcoholic fatty liver disease, cardiovascular risk
Abstract: Non alcoholic fatty liver disease (NAFLD) is defined as fat accumulation exceeding 5% to 10% by the weight of the liver, in the absence of other causes of steatosis. NAFLD is strongly associated with metabolic diseases, such as metabolic syndrome. At present, insulin resistance, elevated concentrations of free fatty acids and oxidants, and an imbalance between different cytokines have been identified as the common pathophysiological elements underlying both NAFLD and metabolic syndrome. Emerging evidence also considers NAFLD as the hepatic manifestation of metabolic syndrome and supports a possible direct role of fat liver in cardiovascular risk assessment. Further investigations are needed to better understand the role of NAFLD, as an independent active factor in metabolic syndrome and associated cardiovascular disease.
Export Options
About this article
Cite this article as:
Montecucco Fabrizio and Mach Francois, Does Non-Alcoholic Fatty Liver Disease (NAFLD) Increase Cardiovascular Risk?, Endocrine, Metabolic & Immune Disorders - Drug Targets 2008; 8 (4) . https://dx.doi.org/10.2174/187153008786848268
DOI https://dx.doi.org/10.2174/187153008786848268 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Carnitine Metabolism and Deficit - When Supplementation is Necessary?
Current Pharmaceutical Biotechnology Advanced Therapies For End-Stage Heart Failure
Current Cardiology Reviews Heart Failure in the Middle East
Current Cardiology Reviews MicroRNAs in Breast Cancer: One More Turn in Regulation
Current Drug Targets Preface [Hot Topic: The Roller Coaster of Antioxidant Therapy (Guest Editor: Francesco Visioli)]
Current Medicinal Chemistry Sex-Genetic Interaction in the Risk for Cerebrovascular Disease
Current Medicinal Chemistry Recent Advances in Management of Diabetic Macular Edema
Current Diabetes Reviews Isotyping the Human TOMM40 Variable-Length Polymorphism by Gene Amplification and Restriction Digest
Current Alzheimer Research Potential Linkage Between Cerebrovascular Diseases and Metabolic Syndrome
Current Drug Metabolism Sirolimus: A Novel Immunosuppressive Drug in Heart Transplantation
Recent Patents on Cardiovascular Drug Discovery Editorial from Guest Editors [Hot Topic: Children with Congenital Heart Disease (Guest Editors: Kris De Boeck and Tony Reybrouck)]
Current Respiratory Medicine Reviews Sex-Gender Differences in Diabetes Vascular Complications and Treatment
Endocrine, Metabolic & Immune Disorders - Drug Targets Novel Biomarkers Assessing Endothelial Dysfunction: Role of microRNAs
Current Topics in Medicinal Chemistry Cardiac Involvement in ANCA (+) and ANCA (-) Churg-Strauss Syndrome Evaluated by Cardiovascular Magnetic Resonance
Inflammation & Allergy - Drug Targets (Discontinued) An Association between MicroRNA-21 Expression and Vitamin D Deficiency in Coronary Artery Disease
MicroRNA Free Radicals Generated by Post-Prandial Oxidative Burst in the Early Alterations of Vascular Contractility
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) “Impact of Smoking Cessation Treatment” on Lung Function and Response Rate in EGFR Mutated Patients: A Short-Term Cohort Study
Recent Patents on Anti-Cancer Drug Discovery New Technological Developments in the Clinical Imaging of Atherosclerotic Plaque
Current Pharmaceutical Design Consumption of Polyphenol Plants May Slow Aging and Associated Diseases
Current Pharmaceutical Design Cysteine Proteinases of Trypanosome Parasites Novel Targets for Chemotherapy
Current Drug Targets